Does exercise beat antidepressants for depression? The head-to-head evidence
In the trial that pitted them against each other, aerobic exercise matched sertraline on remission. But both sat only a little above a strikingly strong placebo, which is the part the headlines skip.
| Group | Value (%) |
|---|---|
| Medication (sertraline) | 47 |
| Supervised exercise | 45 |
| Home-based exercise | 40 |
| Placebo pill | 31 |
The honest answer is that exercise roughly matches antidepressant medication for major depression in the one large trial built to compare them directly — but "matches" is doing more work than the popular version of this claim admits, because in that trial the medication itself barely beat a placebo pill [s1]. So the accurate headline is not "exercise beats drugs." It is that both are reasonable treatments, neither is a knockout, and expectation accounts for a large share of what people feel.
The trial that put them head to head
The clearest test is the SMILE study, a randomised controlled trial published in Psychosomatic Medicine in 2007 [s1]. It enrolled 202 adults with major depression — 153 women and 49 men — and randomly assigned them for 16 weeks to one of four groups: supervised aerobic exercise in a group setting, home-based exercise, the antidepressant sertraline at 50 to 200 mg a day, or a placebo pill [s1]. Assessors were blinded and allocation concealed, which makes it a stronger design than most exercise research [s1].
After four months, 41% of all participants had reached remission — no longer meeting the criteria for major depression and scoring below 8 on the Hamilton depression scale [s1]. The active treatments clustered together and edged out placebo: remission reached 45% with supervised exercise, 40% with home-based exercise and 47% with medication, versus 31% on placebo [s1]. On the continuous Hamilton scores, every group improved, but the active treatments were not significantly better than placebo (p=0.23), and the four-way difference in remission only approached significance (p=0.057) [s1].
That is the result usually quoted as "exercise is as good as antidepressants." It is fair as far as it goes — exercise and sertraline landed within a few percentage points of each other — but it comes with a caveat the slogan drops.
The placebo caveat that reframes it
The reason to be careful is the placebo pill's 31% remission [s1]. When a dummy tablet gets almost a third of people with major depression into remission over four months, the extra ground that either exercise or medication covers is not large [s1]. The trial's own authors drew the obvious conclusion: a considerable portion of the therapeutic response was driven by patients' expectations, ongoing symptom monitoring, attention and other nonspecific factors [s1]. "Exercise beats drugs" and "drugs beat nothing" are both shakier readings of this trial than "structured attention and an active treatment both help, and it is hard to separate them from belief."
What the bigger evidence base adds
A single trial, however well built, cannot settle the question, so the wider synthesis is worth having. The largest is a 2024 network meta-analysis in the BMJ, which pooled 218 randomised trials — 495 treatment arms and 14,170 participants — to compare kinds of exercise against controls, psychotherapy and antidepressants [s2]. Against active controls such as usual care or a placebo tablet, it found moderate reductions in depression for walking or jogging (Hedges' g −0.62, 95% CI −0.80 to −0.45), yoga (−0.55), strength training (−0.49), mixed aerobic exercise (−0.43), and tai chi or qigong (−0.42), with the benefit larger at higher prescribed intensity [s2]. Its conclusion was that these forms of exercise could be considered alongside psychotherapy and antidepressants as core treatments for depression — a place at the table, not a victory over the alternatives [s2].
The same review is candid about how thin the ground still is. Of the 218 trials, only one met the Cochrane criteria for low risk of bias, and confidence in the pooled estimates was rated low for walking or jogging and very low for the other modalities [s2]. A recurring weakness is that participants know whether they are exercising, so expectancy can inflate the effect — the very problem the SMILE placebo exposes [s2].
What it means
For someone weighing the options, the practical upshot is encouraging without being a mandate. Exercise is a legitimate first-line-grade treatment for depression that stands up next to medication in a direct comparison, carries physical-health benefits a pill does not, and suits people who would rather not start a drug [s1][s2]. It is not a proven replacement for medication in severe or treatment-resistant depression, the evidence is weaker than the enthusiasm, and for many people the honest plan is to consider it alongside — not instead of — therapy and antidepressants [s2]. For the pooled picture of exercise versus no treatment, see Cochrane on exercise for depression. This article describes evidence and is not medical advice.
Sources
- Exercise and Pharmacotherapy in the Treatment of Major Depressive Disorder — Psychosomatic Medicine, 2007-09-01
- Effect of exercise for depression: systematic review and network meta-analysis of randomised controlled trials — BMJ, 2024-02-14
Sources
- Exercise and Pharmacotherapy in the Treatment of Major Depressive Disorder — Psychosomatic Medicine , September 1, 2007
- Effect of exercise for depression: systematic review and network meta-analysis of randomised controlled trials — BMJ , February 14, 2024
More on
What helps prolonged grief? A targeted therapy beats an antidepressant
In two randomised trials, a grief-specific psychotherapy roughly doubled response rates against strong comparators. Citalopram alone did not beat placebo — but it did help the depression that often travels with grief.
Adding aripiprazole beat switching drugs in resistant depression in older adults
In a 619-patient NEJM trial of treatment-resistant depression after 60, augmenting an antidepressant with aripiprazole improved well-being more than switching to bupropion. The margin was modest.
Adolescent depression: what the evidence says actually helps
In the largest trial, combining fluoxetine with talking therapy helped most, and both worked better than placebo. A later network analysis found only fluoxetine, alone or with therapy, clearly beat placebo.
Targeting TMS by brain scan beat the ruler-and-scalp method for depression
A 40-person Harvard trial aimed accelerated magnetic stimulation using each patient's own connectivity scan. Depression scores fell further than with standard scalp measurement, though the trial was small.